Lynne Lederman, PhD

A SOHO 2022 presentation by Jason Westin, MD will focus on t on 2 main categories of novel agents that manipulate the immune system to better target aggressive lymphomas.

Many clinicians believe the most significant advance in LBCL treatment in this time is the development of chimeric antigen receptor T-cell therapy.

As more chimeric antigen receptors undergo clinical development for the treatment of hematologic malignancies, their approval for use in a wider array of malignancies is inevitable.

Can treatment with inhibitors of cyclindependent kinases 4 and 6 be optimized for patients with breast cancer? This remains an open question 6 years after the first approval of a CDK4/6 inhibitor, palbociclib.

Agents with novel mechanisms of action distinct from available ATP-competitive tyrosine kinase inhibitors have been tested in patients with previously treated, Philadelphia chromosome–positive chronic myeloid leukemia and offer promise to facilitate deeper remissions.

The incorporation of genomics into the classification and treatment decision-making process for lymphomas is possible; however, many obstacles have prevented the incorporation of sequencing into standard practice, according to Sandeep Dave, MD.

Clinicians are increasingly looking to big data and electronic medical records (EMR) data integration tools in support of clinical decision-making questions and processes for improved access and care for their patients with cancer.

Target capture next-generation sequencing, MassARRAY, and real-time quantitative polymerase chain reaction all effectively detected low frequency somatic epidermal growth factor receptor mutations in cell-free circulating tumor DNA from individuals with non–small cell lung cancer , according to a presentation at the AMP 2020 Annual Meeting and Expo.

Routine testing for the presence of TP53 mutations in myeloid neoplasms by sequencing will become an important part of routine care as TP53-targeting agents become available, according to a poster presented at the Association for Molecular Pathology 2020 Annual Meeting and Expo.

The most recent updated World Health Organization classification of lymphoid neoplasms included a new category of mature B-cell neoplasms, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 translocations.

In the phase III BELIEVE trial, clinically meaningful and durable transfusion burden reduction were observed with luspatercept in the majority of adult patients with β-thalassemia who require regular red blood cell. Additionally, dose levels were not associated with by incidence of adverse events, and these AEs decreases overtime without affecting treatment modification or continuation.

Data from up to 6 years of long-term follow-up shows better progression-free survival, overall survival, objective response rates, and sustained efficacy for patients with chronic lymphocytic leukemia who receive single-agent ibrutinib in earlier lines of treatment, including those with high-risk prognostic factors. According to the poster presented by Paul M. Barr, MD, Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY, during the 2019 American Society of Hematology Annual Meeting, first-line ibrutinib yielded deeper responses over time with 30% complete responses versus 10% to 12% CR for later lines of treatment.

The administration of a higher initial dose of duvelisib at 75 mg BID led to a higher overall response rate of 62% compared with 40% in patients with relapsed/refractory peripheral T-cell lymphoma who received 25 mg BID, according to data from the dose-optimization phase of the PRIMO trial presented at the 2019 American Society of Hematology Annual Meeting.<br /> &nbsp;

In the final analysis of the GADOLIN study in patients with rituximab-refractory indolent non-Hodgkin lymphoma, the combination of obinutuzumab plus bendamustine reduced the risk of progression or death by 43% compared with bendamustine alone. In patients with follicular lymphoma, the reduction was 49%.

Fixed-duration treatment with the combination of venetoclax plus obinutuzumab results in superior progression-free survival and high rates of undetectable minimal residual disease in patients with previously untreated chronic lymphocytic leukemia than chlorambucil plus obinutuzumab.

Obinutuzumab combined with lenalidomide resulted in early and very high complete response rates in previously untreated patients with follicular lymphoma in a single-center phase II study. At a median follow-up of 25 months, the 2-year progression-free survival was 96%.

Selinexor plus lenalidomide and dexamethasone, an all-oral triplet, was found to be highly active in patients with relapsed or refractory multiple myeloma, according to results of the multi-arm STOMP study that were presented during the 17th International Myeloma Workshop. The regimen is also well tolerated and especially active in patients who did not receive lenalidomide prior to the trial.

The combination of melflufen and dexamethasone showed antitumor activity in patients with relapsed or refractory multiple myeloma, both in those with and those without extramedullary disease, according to data from the phase II HORIZON study presented&nbsp;at the 17th International Myeloma Workshop.

The GRIFFIN study showed that the addition of daratumumab to bortezomib, lenalidomide, and dexamethasone, improved stringent complete response in transplant-eligible patients with newly diagnosed multiple myeloma without affecting stem cell mobilization or hematopoietic reconstitution, according to results presented at the 17th International Myeloma Workshop.

Novel agent iberdomide in combination with&nbsp;dexamethasone was safe and demonstrated antitumor activity in patients with relapsed/refractory multiple myeloma who were heavily pretreated, according to findings from a phase Ib/IIa trial presented at&nbsp;the 17th International Myeloma Workshop.

The addition of isatuximab to&nbsp;carfilzomib, lenalidomide, and dexamethasone led to a response rate in all 10 patients included in a safety run-in cohort&nbsp;of the phase II, multicenter GMMG-CONCEPT trial.

Diffuse&nbsp;large B-cell lymphoma is the most common adult non-Hodgkin lymphoma, accounting for about a third of&nbsp;all cases.&nbsp;The World Health Organization classification recognizes over&nbsp;15 subtypes of DLBCL, based on the primary tumor site, specific genetic alterations, or association with specific viruses.

Tumor mutational burden, also referred to as tumor mutational load, is a measure of the number of mutations in tumor tissue taken from a patient. Recently, several studies have been investigating the utility of TMB as a biomarker to predict response to therapy in patients with non&ndash;small cell lung cancer.

Adjuvant therapy for melanoma to lower the risk of disease recurrence and death in patients with high-risk disease who have undergone definitive surgical treatment has previously been administered primarily to patients with stage III disease, as well as a small group of patients with stage IV disease who could be rendered disease free surgically, according to Ahmad A. Tarhini, MD, PhD.

Development of chimeric antigen receptor T-cell therapies is in the works for both hematologic malignancies and solid tumors, but the most promising results to date have been seen with CD19-targeted CAR T cells in the treatment of B-cell acute lymphoblastic leukemia.

Patients with refractory advanced melanoma who had received prior treatment with a checkpoint inhibitor demonstrated promising overall response rate and duration of response in a phase II study involving the antibody-drug conjugate glembatumumab vedotin.

Approximately 25% of patients with <em>BRCA</em> wild-type serous ovarian cancer may benefit from treatment with PARP inhibitors, along with 12.7% of patients with a non-serous histology, according to findings of genomic analyses in patients with ovarian cancer presented during the 2017 ASCO Annual Meeting that&nbsp;demonstrate that comprehensive genomic profiling is a valuable tool to integrate into routine ovarian cancer treatment decision making and clinical trial design.

Lurbinectedin (PM01183) shows activity as a single agent as well as in combination with doxorubicin or paclitaxel in patients with advanced endometrial cancer, according to findings presented during the 2017 ASCO Annual Meeting.

Napabucasin, a first-in-class cancer stemness inhibitor, can be safely combined with full-dose weekly paclitaxel to treat patients with advanced, platinum-resistant ovarian cancer.

Mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, showed promising activity in patients with platinum-resistant ovarian cancer who had received 1 to 3 prior lines of therapy.